GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » Current Ratio

Universal Ibogaine (TSXV:IBO) Current Ratio : 0.39 (As of Apr. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Universal Ibogaine's current ratio for the quarter that ended in Apr. 2025 was 0.39.

Universal Ibogaine has a current ratio of 0.39. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Universal Ibogaine has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Universal Ibogaine's Current Ratio or its related term are showing as below:

TSXV:IBO' s Current Ratio Range Over the Past 10 Years
Min: 0.15   Med: 3.55   Max: 67.67
Current: 0.39

During the past 8 years, Universal Ibogaine's highest Current Ratio was 67.67. The lowest was 0.15. And the median was 3.55.

TSXV:IBO's Current Ratio is ranked worse than
91.55% of 1480 companies
in the Biotechnology industry
Industry Median: 3.69 vs TSXV:IBO: 0.39

Universal Ibogaine Current Ratio Historical Data

The historical data trend for Universal Ibogaine's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine Current Ratio Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
Current Ratio
Get a 7-Day Free Trial 5.23 1.03 0.46 0.16 1.04

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 1.04 0.74 0.49 0.39

Competitive Comparison of Universal Ibogaine's Current Ratio

For the Biotechnology subindustry, Universal Ibogaine's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Universal Ibogaine's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Current Ratio distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Current Ratio falls into.


;
;

Universal Ibogaine Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Universal Ibogaine's Current Ratio for the fiscal year that ended in Jul. 2024 is calculated as

Current Ratio (A: Jul. 2024 )=Total Current Assets (A: Jul. 2024 )/Total Current Liabilities (A: Jul. 2024 )
=1.041/0.998
=1.04

Universal Ibogaine's Current Ratio for the quarter that ended in Apr. 2025 is calculated as

Current Ratio (Q: Apr. 2025 )=Total Current Assets (Q: Apr. 2025 )/Total Current Liabilities (Q: Apr. 2025 )
=0.784/2.012
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Universal Ibogaine  (TSXV:IBO) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Universal Ibogaine Current Ratio Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Universal Ibogaine Business Description

Traded in Other Exchanges
Address
C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
Executives
Ian Rabb Senior Officer

Universal Ibogaine Headlines